Arthur Amron - Nephros Independent Director
| NEPH Stock | USD 2.14 0.05 2.39% |
Director
Mr. Arthur H. Amron is Independent Director of Nephros Inc. Mr. Amron is a Partner of Wexford Capital LP, an SECregistered investment advisor and serves as its General Counsel. Mr. Amron also actively participates in various private equity transactions, particularly in the bankruptcy and restructuring areas, and has served on the boards and creditors committees of a number of public and private companies in which Wexford has held investments. Mr. Amron has also served as a director of Rhino GP LLC, which is the general partner of Rhino Resource Partners LP, a publicly traded master limited partnership, since October 2010. From 1991 to 1994, Mr. Amron was an Associate at Schulte Roth Zabel LLP, specializing in corporate and bankruptcy law, and from 1984 to 1991, Mr. Amron was an Associate at Debevoise Plimpton LLP specializing in corporate litigation and bankruptcy law since 2007.
| Age | 61 |
| Tenure | 17 years |
| Phone | 201 343 5202 |
| Web | https://www.nephros.com |
Arthur Amron Latest Insider Activity
Tracking and analyzing the buying and selling activities of Arthur Amron against Nephros stock is an integral part of due diligence when investing in Nephros. Arthur Amron insider activity provides valuable insight into whether Nephros is net buyers or sellers over its current business cycle. Note, Nephros insiders must abide by specific rules, including filing SEC forms every time they buy or sell Nephros'shares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Arthur Amron over two weeks ago Acquisition by Arthur Amron of 6850 shares of Nephros at 8.06 subject to Rule 16b-3 | ||
Arthur Amron over a month ago Acquisition by Arthur Amron of 91463 shares of Nephros subject to Rule 16b-3 | ||
Arthur Amron over a month ago Acquisition by Arthur Amron of 7000 shares of Nephros at 2.4471 subject to Rule 16b-3 |
Nephros Management Efficiency
The company has return on total asset (ROA) of (0.0871) % which means that it has lost $0.0871 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.1827) %, meaning that it created substantial loss on money invested by shareholders. Nephros' management efficiency ratios could be used to measure how well Nephros manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | DIRECTOR Age | ||
| William Farrell | Pro Dex | 44 | |
| Utama Ayub | Top Glove | 86 | |
| Gregg Lehman | InfuSystems Holdings | 67 | |
| Sebastian Burckhardt | Straumann Holding AG | 64 | |
| Joseph Whitters | InfuSystems Holdings | 60 | |
| Joergen TangJensen | Coloplast A | 61 | |
| Raymond Cabillot | Pro Dex | 54 | |
| Roland Hess | Straumann Holding AG | 64 | |
| Noripah Kamso | Top Glove | 57 | |
| Siew Tong | Top Glove | 55 | |
| Ernst Hoyer | Utah Medical Products | 79 | |
| Regula Wallimann | Straumann Holding AG | 51 | |
| Carsten Hellmann | Coloplast A | 53 | |
| Beat Luethi | Straumann Holding AG | 56 | |
| Jette NygaardAndersen | Coloplast A | 49 | |
| James Beeson | Utah Medical Products | 75 | |
| Pablo Cardenas | Milestone Scientific | 39 | |
| Cheong Lim | Top Glove | 58 | |
| Christopher Sansone | InfuSystems Holdings | N/A | |
| Brian Petersen | Coloplast A | 55 | |
| Rainer Althoff | Top Glove | 67 | |
Management Performance
| Return On Equity | -0.18 | ||||
| Return On Asset | -0.0871 |
Nephros Leadership Team
Elected by the shareholders, the Nephros' board of directors comprises two types of representatives: Nephros inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Nephros. The board's role is to monitor Nephros' management team and ensure that shareholders' interests are well served. Nephros' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Nephros' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Malcom Persen, Director | ||
| Vashone Thomas, Regulatory, Quality | ||
| Thomas Gwydir, Director | ||
| Joleen Turner, VP Devel | ||
| Paul Mieyal, Director | ||
| Greg Lucas, President Systems | ||
| Robert Banks, CEO President | ||
| Alfred Vargas, Director Operations | ||
| Daron Evans, CEO and President Acting CFO, Director and Member of Audit Committee | ||
| Judy CFA, Chief Officer | ||
| Judy Mazzini, Controller | ||
| MS MBA, Inc Products | ||
| Andrew Astor, CFO, CEO | ||
| Alisa Lask, Director | ||
| Matthew Rosenberg, Director | ||
| Moshe Pinto, Director | ||
| Arthur Amron, Independent Director | ||
| Oliver Spandow, Director | ||
| Brianne McGuire, Marketing Brand |
Nephros Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Nephros a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.18 | ||||
| Return On Asset | -0.0871 | ||||
| Profit Margin | (0.11) % | ||||
| Operating Margin | (0.20) % | ||||
| Current Valuation | 19.67 M | ||||
| Shares Outstanding | 10.54 M | ||||
| Shares Owned By Insiders | 11.96 % | ||||
| Shares Owned By Institutions | 40.28 % | ||||
| Number Of Shares Shorted | 2.56 K | ||||
| Price To Earning | (4.51) X |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Nephros. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in american community survey. For more detail on how to invest in Nephros Stock please use our How to Invest in Nephros guide.You can also try the Financial Widgets module to easily integrated Macroaxis content with over 30 different plug-and-play financial widgets.
Complementary Tools for Nephros Stock analysis
When running Nephros' price analysis, check to measure Nephros' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Nephros is operating at the current time. Most of Nephros' value examination focuses on studying past and present price action to predict the probability of Nephros' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Nephros' price. Additionally, you may evaluate how the addition of Nephros to your portfolios can decrease your overall portfolio volatility.
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
| Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios |
Is Nephros' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Nephros. If investors know Nephros will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Nephros listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Nephros is measured differently than its book value, which is the value of Nephros that is recorded on the company's balance sheet. Investors also form their own opinion of Nephros' value that differs from its market value or its book value, called intrinsic value, which is Nephros' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Nephros' market value can be influenced by many factors that don't directly affect Nephros' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Nephros' value and its price as these two are different measures arrived at by different means. Investors typically determine if Nephros is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Nephros' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.